UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 43

Sortiert nach

Double hit lymphoma: the MD Anderson Cancer Center clinical experience

British journal of haematology, 2014-09, Vol.166 (6), p.891-901

2014

Volltextzugriff (PDF)

A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas

Haematologica (Roma), 2020-01, Vol.105 (1), p.e26

2020

Volltextzugriff (PDF)

Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality

Blood, 2001-12, Vol.98 (13), p.3595-3599

2001

Volltextzugriff (PDF)

Follicular dendritic cell sarcoma: A report of 14 cases and a review of the literature

American journal of hematology, 2007-08, Vol.82 (8), p.725-728

2007

Volltextzugriff (PDF)

Positron Emission Tomography/Computed Tomography Findings During Therapy Predict Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy Alone but Not in Those Who Receive Consolidation Radiation

International journal of radiation oncology, biology, physics, 2014-06, Vol.89 (2), p.384-391

2014

Volltextzugriff (PDF)

The Absolute Monocyte and Lymphocyte Prognostic Index for Patients With Diffuse Large B-Cell Lymphoma Who Receive R-CHOP

Clinical lymphoma, myeloma and leukemia, 2013-02, Vol.13 (1), p.15-18

2013

Volltextzugriff (PDF)

Ten‐year follow‐up after intense chemoimmunotherapy with Rituximab‐HyperCVAD alternating with Rituximab‐high dose methotrexate/cytarabine (R‐MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma

British journal of haematology, 2010-07, Vol.150 (2), p.200-208

2010

Volltextzugriff (PDF)

Phase II Study of Denileukin Diftitox for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Journal of clinical oncology, 2004-10, Vol.22 (20), p.4095-4102

2004

Volltextzugriff (PDF)

Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia

Cancer, 2006-04, Vol.106 (7), p.1569-1580

2006

Volltextzugriff (PDF)

Dose‐Adjusted EPOCH‐R and Mid‐Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement

British journal of haematology, 2017-12, Vol.179 (5), p.851-854

2017

Volltextzugriff (PDF)

Ibrutinib-associated Serositis in Mantle Cell Lymphoma

American journal of respiratory and critical care medicine, 2019-06, Vol.199 (12), p.e43-e44

2019

Volltextzugriff (PDF)

Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma

Leukemia & lymphoma, 2021-01, Vol.62 (1), p.58-67

2021

Volltextzugriff (PDF)

‘Watch and Wait’ as Initial Management for Patients with Follicular Lymphomas: Still a Viable Strategy?

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2012-12, Vol.26 (6), p.363-376

Hagemeister, Fredrick B.

2012

Volltextzugriff (PDF)

Phase II trial of denileukin diftitox for relapsed/refractory T‐cell non‐Hodgkin lymphoma

British journal of haematology, 2007-02, Vol.136 (3), p.439-447

2007

Volltextzugriff (PDF)

Hodgkin transformation of chronic lymphocytic leukemia : The M. D. anderson cancer center experience

Cancer, 2006-09, Vol.107 (6), p.1294-1302

2006

Volltextzugriff (PDF)

Dose adjusted‐EPOCH‐R and mediastinal disease may improve outcomes for patients with gray‐zone lymphoma

British journal of haematology, 2017-11, Vol.179 (3), p.503-506

2017

Volltextzugriff (PDF)

Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma

Leukemia & lymphoma, 2013-12, Vol.54 (12), p.2631-2638

2013

Volltextzugriff (PDF)

Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B‐cell non‐Hodgkin lymphoma

British journal of haematology, 2014-10, Vol.167 (2), p.177-184

2014

Volltextzugriff (PDF)

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T‐cell lymphoma

British journal of haematology, 2015-11, Vol.171 (4), p.509-516

2015

Volltextzugriff (PDF)

Maintenance and Consolidation Strategies in Non-Hodgkin’s Lymphoma: A Review of the Data

Current oncology reports, 2010-11, Vol.12 (6), p.395-401

Hagemeister, Fredrick B.

2010

Volltextzugriff (PDF)

Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial

Clinical lymphoma, myeloma and leukemia, 2015-03, Vol.15 (3), p.152-158

2015

Volltextzugriff (PDF)

Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review

Clinical lymphoma, myeloma and leukemia, 2016-03, Vol.16 (3), p.122-128

2016

Volltextzugriff (PDF)

Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial

Clinical lymphoma, myeloma and leukemia, 2013-04, Vol.13 (2), p.99-105

2013

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Aktive Filter

ThemaTreatment Outcome

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(43)

Sprache

Englisch
(43)
Japanisch
(5)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Double hit lymphoma: the MD Anderson Cancer Center clinical experience

A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas

Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality

Follicular dendritic cell sarcoma: A report of 14 cases and a review of the literature

Positron Emission Tomography/Computed Tomography Findings During Therapy Predict Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy Alone but Not in Those Who Receive Consolidation Radiation

The Absolute Monocyte and Lymphocyte Prognostic Index for Patients With Diffuse Large B-Cell Lymphoma Who Receive R-CHOP

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

Ten‐year follow‐up after intense chemoimmunotherapy with Rituximab‐HyperCVAD alternating with Rituximab‐high dose methotrexate/cytarabine (R‐MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma

Phase II Study of Denileukin Diftitox for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial

Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia

Dose‐Adjusted EPOCH‐R and Mid‐Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement

Ibrutinib-associated Serositis in Mantle Cell Lymphoma

Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma

‘Watch and Wait’ as Initial Management for Patients with Follicular Lymphomas: Still a Viable Strategy?

Phase II trial of denileukin diftitox for relapsed/refractory T‐cell non‐Hodgkin lymphoma

Hodgkin transformation of chronic lymphocytic leukemia : The M. D. anderson cancer center experience

Dose adjusted‐EPOCH‐R and mediastinal disease may improve outcomes for patients with gray‐zone lymphoma

Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma

Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B‐cell non‐Hodgkin lymphoma

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T‐cell lymphoma

Maintenance and Consolidation Strategies in Non-Hodgkin’s Lymphoma: A Review of the Data

Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial

Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review

Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial

Aktive Filter

Suchergebnisse filtern